These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28690105)

  • 1. De-escalating and escalating systemic therapy in triple negative breast cancer.
    Carey LA
    Breast; 2017 Aug; 34 Suppl 1():S112-S115. PubMed ID: 28690105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
    Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T; Guiu S; Van Praagh I; Jouannaud C; Dubray-Longeras P; Tubiana-Mathieu N; Benmammar KE; Kullab S; Bahadoor MR; Radosevic-Robin N; Kwiatkowski F; Desrichard A; Cayre A; Uhrhammer N; Chalabi N; Chollet P; Penault-Llorca F
    Ann Oncol; 2014 Aug; 25(8):1570-7. PubMed ID: 24827135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
    Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
    Harbeck N; Gluz O
    Breast; 2017 Aug; 34 Suppl 1():S99-S103. PubMed ID: 28666920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
    J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer.
    Hamm C; Fifield BA; Kay A; Kulkarni S; Gupta R; Mathews J; Ferraiuolo RM; Al-Wahsh H; Mailloux E; Hussein A; Porter LA
    Med Oncol; 2022 Feb; 39(4):49. PubMed ID: 35103812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
    Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
    Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
    Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.
    Rusz O; Papp O; Vízkeleti L; Molnár BÁ; Bende KC; Lotz G; Ács B; Kahán Z; Székely T; Báthori Á; Szundi C; Kulka J; Szállási Z; Tőkés AM
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):139-147. PubMed ID: 29770955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
    Lee A; Go SI; Lee WS; Lee US; Kim MJ; Kang MH; Lee GW; Kim HG; Kang JH; Jeon KN; Cho JM; Lee JH
    Tumori; 2015 Mar; 101(1):e9-e12. PubMed ID: 25702650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment].
    Li Q; Xu B; Li Q; Zhang P; Yuan P; Wang J; Ma F; Luo Y; Fan Y; Cai R
    Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):938-41. PubMed ID: 26887625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
    Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
    Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
    Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
    Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
    Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.